Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study

BACKGROUND: Hepatitis B virus (HBV) reactivation with a hepatitis flare is a common complication in lymphoma patients treated with immunotherapy and/or chemotherapy. Anti-HBV prophylaxis is suggested for non-Hodgkin lymphoma (NHL) patients undergoing rituximab therapy, even those with resolved HBV i...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:PeerJ
Main Authors: Tsai, Yu-Fen, Yang, Ching-I, Du, Jeng-Shiun, Lin, Ming-Hui, Tang, Shih-Hao, Wang, Hui-Ching, Cho, Shih-Feng, Liu, Yi-Chang, Su, Yu-Chieh, Dai, Chia-Yen, Hsiao, Hui-Hua
פורמט: Artigo
שפה:Inglês
יצא לאור: PeerJ Inc. 2019
נושאים:
Gastroenterology and Hepatology
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6741285/
https://ncbi.nlm.nih.gov/pubmed/31565551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7717/peerj.7481
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים